P. Browne, D. Chandraratna, and C. Angood, Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity, Neurology, vol.83, pp.1022-1024, 2014.

F. D. Lublin, S. C. Reingold, and J. A. Cohen, Defining the clinical course of multiple sclerosis: The 2013 revisions, Neurology, vol.83, pp.278-286, 2014.

F. D. Lublin, New multiple sclerosis phenotypic classification, Eur Neurol, vol.72, pp.1-5, 2014.
DOI : 10.1159/000367614
URL : https://www.karger.com/Article/Pdf/367614

M. C. Levin, J. N. Douglas, and L. Meyers, Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms, Degener Neurol Neuromuscul Dis, vol.4, pp.49-63, 2014.
DOI : 10.2147/dnnd.s54391
URL : https://doi.org/10.2147/dnnd.s54391

P. K. Stys, G. W. Zamponi, and M. J. Van, Will the real multiple sclerosis please stand up?, Nat Rev Neurosci, vol.13, pp.507-514, 2012.
DOI : 10.1038/nrn3275
URL : https://prism.ucalgary.ca/bitstream/1880/106648/1/2012_Stys_507NRN.pdf

B. D. Trapp and P. K. Stys, Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis, Lancet Neurol, vol.8, pp.280-291, 2009.

K. Hawker, P. O'connor, and M. S. Freedman, Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized doubleblind placebo-controlled multicenter trial, Ann Neurol, vol.66, pp.460-471, 2009.

H. P. Hartung, R. Gonsette, and N. Konig, Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial, Lancet, vol.360, pp.2018-2025, 2002.
DOI : 10.1016/s0140-6736(02)12023-x

, European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis, Lancet, vol.352, pp.1491-1497, 1998.

D. M. Wingerchuk and J. L. Carter, Multiple sclerosis: Current and emerging disease-modifying therapies and treatment strategies, Mayo Clin Proc, vol.89, pp.225-240, 2014.
DOI : 10.1016/j.mayocp.2013.11.002

F. Sedel, C. Papeix, and A. Bellanger, High doses of biotin in chronic progressive multiple sclerosis: A pilot study, Mult Scler Relat Disord, vol.4, pp.159-169, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01251510

F. Sedel, D. Bernard, and D. M. Mock, Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis, Neuropharmacology. Epub ahead of print, 2015.
DOI : 10.1016/j.neuropharm.2015.08.028
URL : https://doi.org/10.1016/j.neuropharm.2015.08.028

C. Confavreux, S. Vukusic, and T. Moreau, Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, pp.1430-1438, 2000.
DOI : 10.1056/nejm200011163432001

O. Andersen, I. Elovaara, and M. Farkkila, Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.75, pp.706-710, 2004.

J. Chataway, N. Schuerer, and A. Alsanousi, Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebocontrolled, phase 2 trial, Lancet, vol.383, pp.2213-2221, 2014.

J. A. Cohen, G. R. Cutter, and J. S. Fischer, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, vol.59, pp.679-687, 2002.

M. S. Freedman, A. Bar-or, and J. Oger, A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS, Neurology, vol.77, pp.1551-1560, 2011.

R. Kapoor, J. Furby, and T. Hayton, Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebocontrolled, parallel-group trial, Lancet Neurol, vol.9, pp.681-688, 2010.

H. Panitch, A. Miller, and D. Paty, Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study, Neurology, vol.63, pp.1788-1795, 2004.

G. P. Rice, M. Filippi, and G. Comi, Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group, Neurology, vol.54, pp.1145-1155, 2000.

J. S. Wolinsky, P. A. Narayana, O. Connor, and P. , Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, vol.61, pp.14-24, 2007.

O. R. Hommes, P. S. Sorensen, and F. Fazekas, Intravenous immunoglobulin in secondary progressive multiple sclerosis: Randomised placebocontrolled trial, Lancet, vol.364, pp.1149-1156, 2004.
DOI : 10.1016/s0140-6736(04)17101-8

N. G. Wijeratne, J. C. Doery, and Z. X. Lu, Positive and negative interference in immunoassays following biotin ingestion: A pharmacokinetic study, Pathology, vol.44, pp.674-675, 2012.

J. Hobart, A. R. Blight, and A. Goodman, Timed 25-foot walk: Direct evidence that improving 20% or greater is clinically meaningful in MS, Neurology, vol.80, pp.1509-1517, 2013.

A. Manouchehrinia, R. Tanasescu, and C. R. Tench, Mortality in multiple sclerosis: Meta-analysis of standardised mortality ratios, J Neurol Neurosurg Psychiatry, vol.87, pp.324-331, 2015.